Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE-IT trial of AMR101 in statin-treated high-risk hypertriglyceridemic adults
NL-OMON46966Phase 3Active, not recruiting
- Sponsor
- Amarin Corporation plc
- Start
- May 2012
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omega-3-acid triglycerides in hypertriglyceridemia and cardiac morbidity (2 arms), sponsored by Amarin Corporation plc. Primary endpoint: Primary efficacy endpoint. Started May 2012; status: active, not recruiting.
02
Drugs
omega-3-acid triglycerides
03
Conditions
hypertriglyceridemiacardiac morbidity
Beyond the preview
Go deeper on NL-OMON46966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46966.